Protein drug design

We develop protein drugs and transporters through rational in silico design to understand the mechanism behind diseases and how we can treat these.
Immunotherapy is one of the fastest growing fields within drug development. The antibodies that are used and cannot pass cell membranes or the blood-brain barrier (BBB). Hence, they can only reach easily accessible targets unless they are modified. The goal with our research is to open up possibilities to reach new goals. We design and evaluate multispecific antibodies, where some parts bind to the things one wants to modify or detect in a disease and other parts acts as transporters to bring the antibody to its target.
In addition to research, we have also developed and are responsible for the Master's Programme in Biopharmaceuticals, where everyone in the group is involved in the teaching on the different courses.
.png)
An antibody with blood brain barrier transporters. How the transporters are linked to the antibody is important for its function.
Our group
See and contact the members of the group
Gruppmedlemmar
Publications
-
Analyzing and Targeting Post-Translationally Modified Amyloid-β
2026
-
2026
-
Part of Neurotherapeutics, 2025
- DOI for Lowering the affinity of single-chain monovalent BBB shuttle scFc-scFv8D3 prolongs its half-life and increases brain concentration
- Download full text (pdf) of Lowering the affinity of single-chain monovalent BBB shuttle scFc-scFv8D3 prolongs its half-life and increases brain concentration
-
2024
-
Part of Journal of Neurochemistry, p. 413-425, 2023
- DOI for A single-chain fragment constant design enables easy production of a monovalent blood-brain barrier transporter and provides an improved brain uptake at elevated doses
- Download full text (pdf) of A single-chain fragment constant design enables easy production of a monovalent blood-brain barrier transporter and provides an improved brain uptake at elevated doses
- More publications